All In Biotech

Drug Trial Radar · NCT03462719

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

211

Actual

Start

Apr 17, 2018

Primary completion

Feb 26, 2021

Study completion Apr 5, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
Collaborators
Pharmacyclics LLC.
First posted
Mar 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).

Conditions

  • Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

  • IbrutinibDrug

    Participants will receive ibrutinib 420 mg orally once daily up to 15 cycles.

  • VenetoclaxDrug

    Participants will receive venetoclax in combination with ibrutinib for a total of 12 cycles, beginning at Cycle 4. For the first 5 weeks of venetoclax treatment, the treatment dose will be ramped up from 20 to 400 mg.

  • ChlorambucilDrug

    Participants will receive chlorambucil at a dose of 0.5 mg/kg body weight on Days 1 and 15 of Cycles 1 to 6.

  • ObinutuzumabDrug

    Participant will receive obinutuzumab 1000 mg intravenously on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycles 2 to 6.

  • Ibrutinib (as Subsequent Therapy)Drug

    Participants will receive ibrutinib 420 mg orally once daily until disease progression or unacceptable toxicity during the subsequent therapy phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to 2 years 10 months

Locations

88 sites in 14 countries. Site status is shown where the registry gives one.

  • Norton Cancer Institute

    Louisville, Kentucky

  • John Theurer Cancer Center

    Hackensack, New Jersey

  • Novant Health

    Charlotte, North Carolina

  • Institut - Jules Bordet

    Anderlecht, Belgium

  • ZNA Stuivenberg

    Antwerp, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Virga Jessa Ziekenhuis

    Hasselt, Belgium

  • UZ Leuven Gasthuisberg

    Leuven, Belgium

  • Arthur J E Child Comprehensive Cancer Centre

    Calgary, Alberta, Canada

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Juravinski Cancer Centre

    Hamilton, Ontario, Canada

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario, Canada

  • CIUSSS de l Est de l Ile de Montreal Installation Hopital Maisonneuve Rosemont

    Montreal, Quebec, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika

    Brno, Czechia

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Fakultni Nemocnice Ostrava

    Ostrava, Czechia

  • Fakultni nemocnice Plzen, Hemato-onkologicke oddeleni

    Pilsen, Czechia

  • Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie

    Prague, Czechia

  • Aalborg University Hospital

    Aalborg, Denmark

  • Aarhus Universitetshospital

    Aarhus, Denmark

  • Rigshospitalet 1

    Copenhagen, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense Universitetshospital

    Odense C, Denmark

  • Roskilde Sygehus

    Roskilde, Denmark

  • CHU de Clermont Ferrand

    Clermont-Ferrand, France

  • Hopital Claude Huriez

    Lille, France

  • CHU Montpellier

    Montpellier, France

  • Hopital Haut Leveque Service Maladie Du Sang

    Pessac, France

  • Centre Hospitalier Universitaire de Reims, Hôpital Robert Debré

    Reims, France

  • Institut Universitaire du Cancer Toulouse Oncopole

    Toulouse, France

  • CHU Bretonneau

    Tours, France

  • CHU-Nancy

    Vandœuvre-lès-Nancy, France

  • Institut Gustave Roussy

    Villejuif, France

  • Bnai Zion Medical Center

    Haifa, Israel

  • Carmel Medical Center

    Haifa, Israel

  • Hadassah Medical Center

    Jerusalem, Israel

  • Western Galilee Medical Center

    Nahariya, Israel

  • Sheba Medical Center

    Ramat Gan, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.